ArticleFrontiers in oncology2026
Conventional osteosarcoma of the ilium masquerading as a brown tumor in primary hyperparathyroidism: a rare case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coexistence of primary osteosarcoma in the setting of primary hyperparathyroidism (PHPT) is exceedingly rare, and overlapping features between reactive brown tumors and malignancies pose a severe risk of misdiagnosis and diagnostic omission. We report the case of a 65-year-old female who presented with a left hip lesion. Although her clinical manifestations, imaging features, and initial pathology all favored a PHPT-induced brown tumor, a second pathology examination confirmed the coexistence of osteosarcoma within the pelvic lesion. In patients with PHPT, reactive giant cell hyperplasia and cystic degeneration can easily mask the malignant components of osteosarcoma. When encountering "red flags", such as a solitary, extensive bone destruction that is disproportionate to parathyroid hormone (PTH) levels, clinicians must remain vigilant for a concurrent malignant bone tumor and promptly perform expanded sampling to prevent missed diagnoses. Multimodal imaging evaluations and, when necessary, repeated or expanded biopsies are also critical to avoiding misdiagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.